US 12,435,134 B2
Antagonists anti-CD7 antibodies
E-Chiang Lee, Cambridge (GB); Gwenoline Borhis, Cambridge (GB); Cassandra Van Krinks, Cambridge (GB); Lucy Hepburn, Cambridge (GB); Luke Bayliss, Cambridge (GB); and Miha Kosmac, Cambridge (GB)
Assigned to KYMAB LIMITED, Cambridge (GB)
Appl. No. 17/604,209
Filed by KYMAB LIMITED, Cambridge (GB)
PCT Filed Apr. 17, 2020, PCT No. PCT/GB2020/050976
§ 371(c)(1), (2) Date Oct. 15, 2021,
PCT Pub. No. WO2020/212710, PCT Pub. Date Oct. 22, 2020.
Claims priority of application No. 1905552 (GB), filed on Apr. 18, 2019.
Prior Publication US 2022/0324968 A1, Oct. 13, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/02 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01)] 22 Claims
 
1. An antibody or fragment thereof which specifically binds to CD7 (Cluster of Differentiation 7) comprising:
(a) a VH domain which comprises a CDRH1 sequence identical to the amino acid sequence of SEQ ID NO: 1, a CDRH2 sequence identical to the amino acid sequence of SEQ ID NO: 2, and a CDRH3 sequence identical to the amino acid sequence of SEQ ID NO: 3; and a VL domain comprising a CDRL1 sequence identical to the amino acid sequence of SEQ ID NO: 11, a CDRL2 sequence identical to the amino acid sequence of SEQ ID NO: 12, and a CDRL3 sequence identical to the amino acid sequence of SEQ ID NO: 13, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 sequences are defined according to the IMGT system; or
(b) a VH domain which comprises a CDRH1 sequence identical to the amino acid sequence of SEQ ID NO: 4, a CDRH2 sequence identical to the amino acid sequence of SEQ ID NO: 5, and a CDRH3 identical to comprising the amino acid sequence of SEQ ID NO: 6; and a VL domain comprising a CDRL1 sequence identical to the amino acid sequence of SEQ ID NO: 14, a CDRL2 sequence identical to the amino acid sequence of SEQ ID NO: 15, and a CDRL3 sequence identical to the amino acid sequence of SEQ ID NO: 16, wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 sequences are defined according to the Kabat system.